Alaunos Therapeutics Highlights Strategic Priorities And Anticipated Portfolio Milestones For 2023; Alaunos Ended Q4 2022 With Unaudited Cash And Cash Equivalents Of ~$39.1M And Restricted Cash Of ~$13.9M
Announcing addition of two new TCRs to the library, estimated to double the addressable market; plans to further expand TCR library using hunTR® TCR discovery platform
Increasing patient enrollment to